Company news

Moleculin Biotech, Inc. news in 2022

Moleculin Biotech, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

December 20, 2022

Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)

December 14, 2022

Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme

December 6, 2022

Moleculin Reports Third Quarter 2022 Financial Results and Provides Pipeline Update

November 9, 2022

Moleculin to Report Third Quarter 2022 Financial Results on November 10, 2022 and Host Inaugural Quarterly Conference Call and Webcast

November 6, 2022

Moleculin Provides Update on Second Multiple Ascending Dose (MAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

October 13, 2022

Moleculin Biotech WP1122 Portfolio Compound, WP1096, Selected for NIAID-Funded Animal Studies as Novel Potential Antiviral

September 26, 2022

Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme

September 5, 2022

Moleculin Announces Completion of Third Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

August 18, 2022

Moleculin Reports Second Quarter 2022 Financial Results and Provides Programs Update

August 14, 2022

Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

July 27, 2022

Moleculin Announces Completion of Second Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

July 7, 2022

Moleculin Announces Completion of First Single Ascending Dose (SAD) Cohort in Phase 1a Clinical Trial of WP1122 in the UK

June 15, 2022

Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

May 25, 2022

Moleculin Reports First Quarter 2022 Financial Results and Provides Programs Update

May 11, 2022

Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

May 9, 2022

Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)

May 4, 2022

Moleculin Engages Wolfram C. M. Dempke, MD, PhD, MBA as its European Chief Medical Officer

May 3, 2022

Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma

April 20, 2022

Moleculin Announces Corporate Rebranding and Launch of New Website

April 13, 2022

Moleculin Reports Full Year Financial Results and Provides Programs Update

March 24, 2022

Moleculin Announces Appointment of Joy Yan, M.D., Ph.D. to Board of Directors

February 28, 2022

Moleculin Provides Annamycin AML Program Update and Outlines Next Steps to Advance Towards Late-Stage Development

February 13, 2022

Moleculin Announces Updated Preliminary Safety Data for Annamycin in Its Three Phase 1 Clinical Trials for Acute Myeloid Leukemia and Metastases of Soft Tissue Sarcoma

January 17, 2022

Calls in 2022

Decks in 2022